Confo Therapeutics
PrivateLast Round
Series B
Jul 26, 2024
Total Funding Raised
$115.57M
Company Overview
Confo Therapeutics is a biotechnology company that develops novel GPCR-directed medicines for metabolic and endocrine diseases using its proprietary Confo® technology platform.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Confo Therapeutics Comparables
Compare Confo Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Domain Therapeutics | 81% | |
| Nxera Pharma | 80% | |
| leadXpro AG | 80% |
Confo Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 26, 2024 | ||||
| Grant | Mar 28, 2024 | ||||
| Grant | Jun 28, 2022 | ||||
| Grant | Mar 30, 2021 | ||||
| Grant | Jun 20, 2019 | ||||
Series A | May 7, 2019 |
Key People
Founding team and executive leadership
Confo Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ackermans & van Haaren | Series B |
| Capricorn Partners | Series B, Seed |
| Perceptive Advisors | Series A, Series B |
| Fund+ | Series A, Series B |
| Capricorn Health-tech Fund | Series A, Seed, Series B |
| V-Bio Ventures | Series A, Seed, Series B |
| VLAIO | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 16, 2026
Monthly visitors grew 39% MoM, reaching 7.9K.
- Jul 26, 2024
$65M round led by Ackermans & van Haaren.
Confo Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Confo Therapeutics's valuation, stock price, and market status.
Is Confo Therapeutics a public or private company?
Confo Therapeutics is a private company.
What is the current stock price of Confo Therapeutics?
Confo Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Confo Therapeutics worth (valuation)?
Valuation information for Confo Therapeutics is not publicly available.
Can I buy Confo Therapeutics stock?
Confo Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Confo Therapeutics's last funding round?
Confo Therapeutics's most recent funding round was Series B on July 26, 2024.
Who are the main investors in Confo Therapeutics?
Key investors in Confo Therapeutics include Ackermans & van Haaren, Capricorn Partners, VLAIO, Wellington Partners, BioGeneration Ventures.
Will Confo Therapeutics IPO soon?
No public IPO plans have been announced for Confo Therapeutics.
How can I track Confo Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Confo Therapeutics's secondary market activity and sign up for updates.